All News
Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn
Richard Conway RichardPAConway ( View Tweet)
SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA
Eric Dein ejdein1 ( View Tweet)
@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
Olga Petryna DrPetryna ( View Tweet)
No need to stop Tofa w/the flu?
👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB.
👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar.
Abstr#L04 #ACR20 @rheumnow #ACRBest
https://t.co/rZXKRVl7uK
k dao KDAO2011 ( View Tweet)
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Robert B Chao, MD doctorRBC ( View Tweet)
Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1
Dr. John Cush RheumNow ( View Tweet)
#ACR20👀🔥🔥@AliDuarteMD Population epi revealed:
⭐️Markedly increased SLE incidence
⭐️Drastically increased SLE prevalence
Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk
Yu (Ray) Zuo RayZuoMD ( View Tweet)
UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI
Dr. Rachel Tate uptoTate ( View Tweet)
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Read Article
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary
Peter Nash drpnash ( View Tweet)
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Robert B Chao, MD doctorRBC ( View Tweet)
Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
Dr. Rachel Tate uptoTate ( View Tweet)
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update.
Beautiful organization of targeted therapy in multiple autoimmune diseases.
Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC ( View Tweet)
This convinces me! #TNF inhibitors vs #JAKI
great debate at #ACR20 https://t.co/Xb8KkmDJ8f
KenWarringtonMD MdWarrington ( View Tweet)
New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369
Dr. Antoni Chan synovialjoints ( View Tweet)
Important study helping dissect the JAK-IFN axis I believe - we need to be cautious in attacking this axis as anifrolumab has >2x Zoster of JAKi's- we need to read the tea leaves from IEIs and COVID-19 #ACR20 @JYazdanyMD @Lupusdoc @casanova_lab @cannalab1 https://t.co/scI13jwFZd
Leonard Calabrese LCalabreseDO ( View Tweet)
Lots of JAK safety studies in #ACR20. Abst#0237 pooled 5 RCTs on UPA. Good safety numbers and low VTE rates, but watch out for herpes zoster trend, elevated in UPA (30>15mg) compared to MTX and ADA. @RheumNow
Eric Dein ejdein1 ( View Tweet)